Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2964 participants.
Also called NCT02879305
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,964 participants
- Sponsor
- Registry
-
NCT02879305 -
2016-000541-31
-
- Other papers using this trial's data
- Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Estonia, France, Germany, Greece, Hungary, India, Italy, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02879305. Randomized; no masking; primary purpose treatment. Start 2016-09-28 (actual); primary completion 2020-11-09 (actual). Results posted on 2021-12-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
- Condition
- Anaemia
- Condition
- Aspergillosis, Allergic Bronchopulmonary
- Intervention (Drug)
- Daprodustat
- Intervention (Drug)
- rhEPO
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Iron therapy
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct02879305- Content hash
fbd83bf7fe4266073b83dd92d8b9e8b7f7b931cb219674496f4693aadf4deaf1